Guangdong Marubi Biotechnology Co Net Assets
Guangdong Marubi Biotechnology Co net assets. Based on the latest financial reports, Guangdong Marubi Biotechnology Co (603983) has net assets worth CN¥3.44 Billion CNY (≈ $503.04 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.63 Billion ≈ $677.97 Million USD) and total liabilities (CN¥1.20 Billion ≈ $174.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Guangdong Marubi Biotechnology Co net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.44 Billion |
| % of Total Assets | 74.2% |
| Annual Growth Rate | 25.07% |
| 5-Year Change | 7.46% |
| 10-Year Change | 309.88% |
| Growth Volatility | 31.17 |
Net Assets of Guangdong Marubi Biotechnology Co (2011–2025)
Net assets of Guangdong Marubi Biotechnology Co from 2011 to 2025. This chart illustrates how Guangdong Marubi Biotechnology Co's net assets have evolved over time, based on quarterly financial data. Also explore 603983 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Guangdong Marubi Biotechnology Co (2011–2025)
The table below shows the annual net assets of Guangdong Marubi Biotechnology Co from 2011 to 2025. For live market cap and overall valuation, see how much is Guangdong Marubi Biotechnology Co worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.39 Billion ≈ $496.67 Million |
-1.52% |
| 2024-12-31 | CN¥3.45 Billion ≈ $504.33 Million |
+0.82% |
| 2023-12-31 | CN¥3.42 Billion ≈ $500.24 Million |
+5.10% |
| 2022-12-31 | CN¥3.25 Billion ≈ $475.96 Million |
+2.98% |
| 2021-12-31 | CN¥3.16 Billion ≈ $462.18 Million |
+5.26% |
| 2020-12-31 | CN¥3.00 Billion ≈ $439.09 Million |
+12.39% |
| 2019-12-31 | CN¥2.67 Billion ≈ $390.69 Million |
+93.21% |
| 2018-12-31 | CN¥1.38 Billion ≈ $202.21 Million |
+43.95% |
| 2017-12-31 | CN¥959.96 Million ≈ $140.47 Million |
+15.92% |
| 2016-12-31 | CN¥828.09 Million ≈ $121.18 Million |
+15.67% |
| 2015-12-31 | CN¥715.92 Million ≈ $104.76 Million |
+18.43% |
| 2014-12-31 | CN¥604.48 Million ≈ $88.45 Million |
+33.41% |
| 2013-12-31 | CN¥453.11 Million ≈ $66.30 Million |
+92.92% |
| 2012-12-31 | CN¥234.87 Million ≈ $34.37 Million |
+58.68% |
| 2011-12-31 | CN¥148.02 Million ≈ $21.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Marubi Biotechnology Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1908.1% over the analyzed period, indicating profitable operations and earnings retention.
Guangdong Marubi Biotechnology Co Net Assets Breakdown (December 2025)
Guangdong Marubi Biotechnology Co net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.97 Billion | 59.01% |
| Other Components | CN¥1.37 Billion | 40.99% |
| Total Equity | CN¥3.33 Billion | 100.00% |
Guangdong Marubi Biotechnology Co Competitors by Market Cap
The table below lists competitors of Guangdong Marubi Biotechnology Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GCS Holdings
TWO:4991
|
$1.49 Billion |
|
NP3 Fastigheter AB
ST:NP3
|
$1.49 Billion |
|
The South Indian Bank Limited
NSE:SOUTHBANK
|
$1.49 Billion |
|
Tibet Summit Resources Co Ltd
SHG:600338
|
$1.49 Billion |
|
Ouster, Inc. Common Stock
NYSE:OUST
|
$1.49 Billion |
|
Indegene Ltd
NSE:INDGN
|
$1.49 Billion |
|
Guodian Nanjing Automation Co Ltd
SHG:600268
|
$1.49 Billion |
|
Accelevation Holdings Corp. Class A Ordinary Shares
NASDAQ:ACCV
|
$1.49 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Marubi Biotechnology Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,380,406,892 to 3,331,157,902, a change of -49,248,990 (-1.5%).
- Net income of 247,239,141 contributed positively to equity growth.
- Dividend payments of 300,885,417 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥247.24 Million | +7.42% |
| Dividends Paid | CN¥300.89 Million | -9.03% |
| Other Changes | CN¥4.40 Million | +0.13% |
| Total Change | CN¥- | -1.46% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Marubi Biotechnology Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 69.00x to 3.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.37 | CN¥25.35 | x |
| 2012-12-31 | CN¥0.62 | CN¥25.35 | x |
| 2013-12-31 | CN¥1.26 | CN¥25.35 | x |
| 2014-12-31 | CN¥1.67 | CN¥25.35 | x |
| 2015-12-31 | CN¥1.98 | CN¥25.35 | x |
| 2016-12-31 | CN¥2.28 | CN¥25.35 | x |
| 2017-12-31 | CN¥2.68 | CN¥25.35 | x |
| 2018-12-31 | CN¥3.81 | CN¥25.35 | x |
| 2019-12-31 | CN¥6.66 | CN¥25.35 | x |
| 2020-12-31 | CN¥7.43 | CN¥25.35 | x |
| 2021-12-31 | CN¥7.69 | CN¥25.35 | x |
| 2022-12-31 | CN¥7.95 | CN¥25.35 | x |
| 2023-12-31 | CN¥8.39 | CN¥25.35 | x |
| 2024-12-31 | CN¥8.41 | CN¥25.35 | x |
| 2025-12-31 | CN¥8.31 | CN¥25.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Marubi Biotechnology Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.42%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.15%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.38x
- Recent ROE (7.42%) is below the historical average (32.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 113.31% | 27.28% | 1.03x | 4.04x | CN¥152.50 Million |
| 2012 | 79.69% | 22.93% | 1.16x | 3.01x | CN¥163.43 Million |
| 2013 | 48.25% | 22.45% | 1.04x | 2.07x | CN¥173.30 Million |
| 2014 | 44.89% | 25.23% | 0.89x | 1.99x | CN¥210.93 Million |
| 2015 | 39.31% | 23.63% | 0.87x | 1.91x | CN¥209.84 Million |
| 2016 | 28.04% | 19.22% | 0.82x | 1.78x | CN¥149.38 Million |
| 2017 | 32.49% | 23.07% | 0.84x | 1.67x | CN¥215.92 Million |
| 2018 | 30.20% | 26.35% | 0.74x | 1.54x | CN¥277.76 Million |
| 2019 | 19.28% | 28.59% | 0.52x | 1.29x | CN¥247.90 Million |
| 2020 | 15.60% | 26.61% | 0.46x | 1.27x | CN¥166.62 Million |
| 2021 | 8.04% | 13.87% | 0.48x | 1.22x | CN¥-60.49 Million |
| 2022 | 5.46% | 10.06% | 0.42x | 1.28x | CN¥-144.62 Million |
| 2023 | 7.75% | 11.66% | 0.50x | 1.33x | CN¥-75.30 Million |
| 2024 | 10.11% | 11.50% | 0.59x | 1.50x | CN¥3.59 Million |
| 2025 | 7.42% | 7.15% | 0.75x | 1.38x | CN¥-85.88 Million |
Industry Comparison
This section compares Guangdong Marubi Biotechnology Co's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $1,204,496,032
- Average return on equity (ROE) among peers: 5.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Marubi Biotechnology Co (603983) | CN¥3.44 Billion | 113.31% | 0.35x | $1.49 Billion |
| Lonkey Industrial Co Ltd Guangzhou (000523) | $388.65 Million | -29.78% | 0.42x | $789.65 Million |
| Tianjin Yiyi Hygiene Products Co Ltd (001206) | $1.81 Billion | 8.32% | 0.12x | $443.99 Million |
| Hunan Resun Co Ltd (001218) | $2.14 Billion | 6.34% | 0.27x | $401.94 Million |
| Qingdao Kingking Applied Chemistry Co Ltd (002094) | $455.94 Million | 7.68% | 0.94x | $465.06 Million |
| C&S Paper Co Ltd (002511) | $2.70 Billion | 9.66% | 0.67x | $1.29 Billion |
| Anhui Deli Household Glass Co Ltd (002571) | $901.74 Million | 5.93% | 0.28x | $561.50 Million |
| Mingchen Health Co Ltd Class A (002919) | $229.96 Million | 18.92% | 1.06x | $663.61 Million |
| Chongqing Baiya Sanitary Products Co (003006) | $1.45 Billion | 19.84% | 0.48x | $1.49 Billion |
| Chengdu Rainbow Appliance Gr (003023) | $1.44 Billion | 6.57% | 0.37x | $337.74 Million |
| Fujian Green Pine Co Ltd (300132) | $531.51 Million | 3.98% | 0.59x | $466.40 Million |
About Guangdong Marubi Biotechnology Co
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company offers eye care, skincare, cleansing, and beauty and other products. It sells its products under the Marubi, Lianhuo, Chunji, and Passional Lover brands. The company was founded in 2002 and is based in Guangzhou, China.